Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 25Breast Neoplasms 14Neoplasms 12Myelodysplastic Syndromes 12Prostatic Neoplasms 10Multiple Myeloma 8Lung Neoplasms 7Stomach Neoplasms 6Sarcoma 6Ovarian Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Recurrence 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumor 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Small Cell Lung Carcinoma 3Pain 3Mucositis 3Lymphoma, T-Cell, Peripheral 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Stomatitis 2Skin Neoplasms 2

Interventions

Cyclophosphamide 23fludarabine phosphate 20Cyclosporine 19Busulfan 17Peripheral Blood Stem Cell Transplantation 14Mycophenolic Acid 14Antilymphocyte Serum 13Whole-Body Irradiation 12Radiotherapy 11Cord Blood Stem Cell Transplantation 10Methotrexate 9Filgrastim 9Methylprednisolone 8Cytarabine 6sargramostim 5Tacrolimus 5Melphalan 5Etoposide 5Cyclosporins 4merphos 3fludarabine 3Transplantation 3Thiotepa 3Granulocyte Colony-Stimulating Factor 3Decitabine 3bryostatin 1 2aldesleukin 2Topotecan 2Thioguanine 2Thalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anemia, Refractory × Injections × Clear all
NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
8 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡